UBS Group
DWTX

UBS Group’s Dogwood Therapeutics DWTX Stock Holding History

UBS Group’s Portfolio DWTX Stock Details DWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3K Sell
1,860
-5,225
-74% -$8.65K ﹤0.01% 9253
2026
Q1 		$14.9K Buy
7,085
+5,337
+305% +$15.7K ﹤0.01% 8141
2025
Q4 		$7.27K Buy
+1,748
New +$10.3K ﹤0.01% 8459
2025
Q2 		– Sell
-29,818
Closed -$149K – 11048
2025
Q1 		$149K Buy
29,818
+12,147
+69% +$82.2K ﹤0.01% 6746
2024
Q4 		$44K Buy
17,671
+10,229
+137% +$33.9K ﹤0.01% 7382
2024
Q3 		$31.6K Buy
7,442
+1,371
+23% +$7.11K ﹤0.01% 7103
2024
Q2 		$32.6K Buy
+6,071
New +$52.5K ﹤0.01% 7006
2024
Q1 		– Sell
-104
Closed -$1.5K – 10145
2023
Q4 		$1.5K Buy
+104
New +$1.75K ﹤0.01% 8291
2023
Q3 		– Sell
-11
Closed -$366 – 10065
2023
Q2 		$366 Sell
11
-54
-83% -$1.54K ﹤0.01% 8272
2023
Q1 		$600 Buy
+65
New +$517 ﹤0.01% 8964
2022
Q4 		– Sell
-1,642
Closed -$16K – 11234
2022
Q3 		$16K Buy
+1,642
New +$231K ﹤0.01% 7722
2022
Q2 		– Sell
-565
Closed -$63K – 11065
2022
Q1 		$63K Buy
565
+475
+528% +$69.1K ﹤0.01% 6267
2021
Q4 		$12K Buy
+90
New +$11.4K ﹤0.01% 8588
2021
Q3 		– Sell
-533
Closed -$84K – 10189
2021
Q2 		$84K Buy
+533
New +$75.6K ﹤0.01% 6021
2021
Q1 		– Sell
-133
Closed -$25K – 9567
2020
Q4 		$25K Buy
+133
New +$32.1K ﹤0.01% 6786

Other funds holding DWTX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group's DWTX Position: Q2 2026 in Review

UBS Group reduced its Dogwood Therapeutics (DWTX) stake by 74% in Q2 2026, selling an estimated $8.65K and leaving 1,860 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #9253.

UBS Group first reported a position in DWTX in Q4 2020 and has held it in 15 quarters since. The position peaked at $149K in Q1 2025. 15 funds tracked by Wall St. Rank hold DWTX as of Q2 2026.

  • UBS Group held 1,860 shares of Dogwood Therapeutics worth $3K as of Q2 2026.
  • UBS Group sold 5,225 Dogwood Therapeutics shares in Q2 2026, an estimated $8.65K.
  • Dogwood Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9253 holding.
  • UBS Group first reported a position in Dogwood Therapeutics in Q4 2020 and has held it in 15 quarters since.
  • UBS Group's Dogwood Therapeutics position peaked at $149K in Q1 2025.
  • 15 funds tracked by Wall St. Rank held Dogwood Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.